Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04395508
Title An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Genentech, Inc.
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Beverly Hills Cancer Center Beverly Hills California 90211 United States Details
UCSF Helen Diller Family CCC San Francisco California 94158 United States Details
Stanford Univ School of Med; Oncology Stanford California 94305-5821 United States Details
University Of Colorado Aurora Colorado 80045 United States Details
MedStar Washington Hosp Center Washington District of Columbia 20010 United States Details
Mayo Clinic-Jacksonville Jacksonville Florida 32224 United States Details
University of Maryland School of Medicine Baltimore Maryland 21201 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Mayo Clinic Hospital-Rochester, St. Marys Campus - PPDS Minneapolis Minnesota 55455 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
University of Washington Seattle Cancer Care Alliance Seattle Washington 98195 United States Details
*Shaded cells indicate that there was no data available from for the field